PPI Products Must Warn Of Possible Increased Fracture Risk - FDA
This article was originally published in The Tan Sheet
Executive Summary
FDA requires manufacturers to warn consumers that using proton pump inhibitors could increase the risk of some fractures, even though current research does not establish a causal link between the drug and fracture risk
You may also be interested in...
In Brief
FDA reverses on OTC PPI fracture risk
In Brief
C&D may cover costs by raising prices
Study Questions “Liberal” Proton Pump Inhibitor Use
A Canadian study supporting a link between proton pump inhibitors and osteoporosis-related fractures could lead to questions about OTC access to PPIs and shows a need to educate consumers regarding individual fracture risk, the authors say